Purpose: To evaluate the incidence of increased intraocular pressure (iOP) in individuals with a history of steroid res lonsiveness when challenged with rimcxolone. Methods: Individuals with a history of increased iOP to either topical or oral corticosteroids were recruited in this ongoing study. Following IRB approval and informed consent 5 subjet ts to date have been challenged with rimexolone l%(VexoI, Alcon Laborato -ies, Inc.). Subjects could have glaucoma, uveitis or no ocular disease but their IOP had to he controlled and no active inflammation could be present. Subjec's could not be on any corticosteroid medication or topical beta-blocker. Following baseline evaluation rimcxolone 1 % was started in one eye for up to 6 week; with iOP assessment every 1 lo 2 weeks. If IOP increased greater than 8mm Hg tne medication was stopped. Results: Intraocular pressure increased 17mm H j and 15 mm Hg following 4 and 6 weeks respectively in two of five subjects when challenged with rimexolone. Conclusions: Despite reports suggesting a reduced risk of steroid responsiveness with rimexolone, significant elevations :>f intraocular pressure may occur.
|Original language||English (US)|
|Journal||Investigative Ophthalmology and Visual Science|
|State||Published - Dec 1 1997|
ASJC Scopus subject areas
- Sensory Systems
- Cellular and Molecular Neuroscience